Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…
News
Brain and spinal cord lesions resolve less often in children with neuromyelitis optica spectrum disorder (NMOSD) than with myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a related disorder, according to a small study. No significant differences in resolving lesions were seen between children with NMOSD and those with multiple…
CCL2, a signaling protein that recruits immune cells to sites of injury, may play a key role in driving the nerve damage that results from antibodies against the aquaporin-4 (AQP4) protein in neuromyelitis optica spectrum disorder (NMOSD), a study suggests. The signaling protein was found to be elevated in…
Out of four markers of nervous system cell injury, blood levels of neurofilament light chain (NfL) were found to best predict disability worsening in people with neuromyelitis optica spectrum disorder (NMOSD), a study showed. Measures of blood NfL levels at the time of an NMOSD attack were the only ones…
Ultomiris (ravulizumab) has been approved by authorities in Japan to prevent relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) positive for antibodies against aquaporin-4 (AQP4). The decision from the Japanese Ministry of Health, Labour and Welfare comes shortly after a similar approval by the European Commission,…
In a racially diverse group of people with neuromyelitis optica spectrum disorder (NMOSD), rituximab worked better to prevent relapses than did oral immunosuppressive therapies, a single-center U.S. study showed. This result was particularly relevant for Black patients — who are usually underrepresented in NMOSD clinical trials but who, the…
The risk of neuromyelitis optica spectrum disorder (NMOSD) attacks following vaccination is low, and such attacks have not been found to be associated with any particular type of vaccine, according to a review study. Also, post-vaccine attacks tended to happen more frequently in men, patients negative for antibodies against…
A small subset of people with neuromyelitis optica spectrum disorder (NMOSD) do not accumulate significant functional disability in the 15 years following symptom onset, according to a recent study. Called benign NMOSD, these patients were more likely to be Caucasian, less likely to have spinal cord involvement at disease…
SPHERES, a real-world registry for neuromyelitis optica spectrum disorder (NMOSD), is now collecting biological samples from consenting participants. Launched by CorEvitas and the Guthy-Jackson Charitable Foundation (GJCF) in 2021, the registry had been collecting long-term clinical data, but not biological samples. “The launch of this biospecimen…
Ultomiris (ravulizumab) has been approved by the European Commission to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4). “Effective NMOSD management hinges on reducing relapses – even a single relapse may cause irreversible disabilities leaving patients unable to move, speak…
Recent Posts
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD
- Advanced plasma exchange therapy effectively eases NMOSD attacks
- Reaffirming that access to healthcare is a human right
- Brain, spinal cord shrinkage linked to distinct NMOSD outcomes: Study
- Reflecting on what I’m grateful for softens the edges of NMOSD
- When my invisible illness meets my very visible disabled parking spot
- Study IDs environmental factors tied globally to higher NMOSD risk
- Inflammatory protein S100A9 ID’d as new treatment target in NMOSD
- Connecting with others who have NMOSD gave me hope